期刊文献+

HBV前C区1896点突变的检测及意义 被引量:1

Detection of 1896 dot mutation located in hepatitis B virus pre C and the clinical significance
暂未订购
导出
摘要 目的 探讨HBV前C区 1896点突变的临床意义。方法 采用PCR ELISA检测技术 ,对 14 8例HBeAg阴性 ,HBV DNA阳性乙型肝炎病毒感染者HBV前C区 1896点突变基因分析 ,40例对照组 ,分成对照 1组和对照 2组 ,处理方法同实验组。结果 实验组中 69 8%HBV发生 1896点突变 ,对照 1组 5 %发生点突变 ,对照 2组无阳性。结论 HBeAg阴性不能认为无传染性及DNA复制 ,所以建议应同时检测HBV1896和HBV DNA。 Objective To study the clinical significance of 1896 dot mutation in HBV pre C Methods 1896 dot mutation was examined in 148 patients whith negative HBeAg and positive HBV DNA by PCR ELISA 40 cases of subjects were divided into two control groups and treated in the same way as the experiment group Results Experiment group had a positive rate of 69 8%;Control group Ⅰ had a positive rate of 5% and there was no positive rate in control group Ⅱ Conclusion Negative HBeAg may be infectious and cause DNA copy So,it is necessary to detect HBV 1896 and HBV DNA at the same time
出处 《四川医学》 CAS 2003年第11期1113-1114,共2页 Sichuan Medical Journal
关键词 乙肝病毒 点突变 hepatitis B virus dot mutation
  • 相关文献

参考文献2

二级参考文献3

共引文献10

同被引文献24

  • 1庄辉.乙型肝炎流行病学研究进展[J].国外医学(流行病学.传染病学分册),2004,31(3):133-135. 被引量:149
  • 2姚光弼,张定凤,王宝恩,徐道振,周霞秋,雷秉钧.恩替卡韦抗乙型肝炎病毒剂量和疗效的研究[J].中华肝脏病杂志,2005,13(7):484-487. 被引量:117
  • 3Davey S. State of the World's Vaccines and Immunization [M]. Geneva:World Health organization,1996:76.
  • 4Alexopoulou A, karayiannis P, Hadziyamis SJ,et al. Whole genome analysis B virus form four case of folminant hepatitis: genetic varizbiliby and its potential role in disease pathogeniel- ty[J]. J Viral Hepatol,1996,3(4):173-181.
  • 5Kuwahara R, Kumashiro R, Murashima S, et al. Precore stop eodon mutation of hepatitis B virus is associated wit h low breakthrough rate following longterm lamivudine thera- py[J]. J Gast roenterol Hepatol,2005,20(6) :844-849.
  • 6Chen CH, Lee CM, Lu SN,et al. Comparison of sequence changes of precore and core promoter regions in HBeAg-pos- itive chronic hepatitis B patients with and without HBeAg clearance in lamivudine therapy[J]. J Hepatol, 2006,44 (1) 76-82.
  • 7Lok AS, Lai CL, Leung N, et al. Long-term safety of lami- vudine treatment in patients with chronic hepatitis B[J]. Gastroenterology, 2003,125 (6) :1714-1722.
  • 8Mareellin P, Chang TT, Lira SG, et al. Adefovir dipivoxil for the treatment of hepatitis Be antigen-positive chronic hep- atitisB[J]. N Engl J Med,2003,348(9):808-816.
  • 9Macellin P, Chang TT, Lim S, et al. Long term efficacy and safety of adefovir dipivoxil 10 mg in HBeAg+ chronic hepati- tis B patients: increasing serologic, virologic and biochemical response over time [ J ]. Hepatology, 2004, 40 ( 4, suppl. ) :S655A.
  • 10Hadziyannis SJ, Tassopoulos NC, Heathcote E J, et al. Ade- fovir dipivoxil for the treatment of hepatitis Be antigen-nega- tive chronic hepatitis B[J]. N Engl J Med,2003,348(9) :800- 807.

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部